Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD 0332334 and Paroxetine in Generalized Anxiety Disorder
NCT00836069Phase 3Terminated
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Oct 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of imagabalin in generalized anxiety disorder (GAD), sponsored by Cedars-Sinai Medical Center. Started Oct 2008; status: terminated.
02
Drugs
imagabalin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00836069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00836069.